ESMO Congress 2019: ESMO Colloquia

The ESMO Colloquia are innovative new sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.

The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

View the complete ESMO Congress 2019 programme online

Saturday, 28 September 2019

ESMO Colloquium: Emerging biotherapy strategies in the treatment of solid tumours: Hope, Hype and Hurdles

Emerging-Biotherapy-Strategies-in-the-Treatment-of-Solid-Tumours-Hope-Hype-and-Hurdles-EISAI-Thumb

Toledo Auditorium, 13:00-14:30
This educational activity is provided by ESMO and funded by Eisai Europe Ltd.
View the ESMO colloquium details

Learning Objectives

  • Understand how the development of TKI have changed practice and treatment prioritization
  • Review the overall outcome with the development of Immuno-Oncology and practice changes
  • Look forward to the development of Combined approaches with TKI and immuno-oncology

Sunday, 29 September 2019

ESMO Colloquium: Metastatic clear cell renal cell carcinoma: How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?

Metastatic-Clear-Cell-Renal-Cell-Carcinoma-What-Is-the-Best-Sequence-in-A-Multi-Line-Setting-IPSEN-Thumb

Cordoba Auditorium, 18:30-20:00
This educational activity is provided by ESMO and supported by Ipsen.
View the ESMO colloquium details

Learning Objectives

  • Review the 2019 algorithms from the ESMO Guidelines for the management of Renal Cell Carcinoma
  • Compare the outcome and clinical benefit (ESMO-MCBS) of the various therapeutic options according to risk factors upfront and in later lines.
  • Discuss the best sequencing of drug use considering the large choice of approved agents

Sunday, 29 September 2019

ESMO Colloquium: Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)

Relapsed-Refractory-FLT3-ITD-Mutated-Acute-Myeloid-Leukemias-AML-DAIICHI-SANKYO-Thumb

Toledo Auditorium, 18:30-20:00
This educational activity is provided by ESMO and supported by Daiichi Sankyo Europe GmbH.
View the ESMO colloquium details

Learning Objectives

  • Review the present characteristics and Guidelines for the management of Relapsed/Refractory AML
  • Understand the mechanism of action of FLT3 and its role in AML when mutated
  • Review the recent outcomes of FLT3-ITD as a target in Relapsed/Refractory AML

Sunday, 29 September 2019

ESMO Colloquium: Metastatic gastro-intestinal cancer: Multiple treatment lines, extended pipeline of available drugs and use of predictive markers. How to best sequence the treatment proposal?

Metastatic-Gastro-Intestinal-Cancer-How-to-Best-Sequence-the-Treatment-Proposal-LILLY-Thumb

Alicante Auditorium, 18:30-20:00
This educational activity is provided by ESMO and supported by Lilly Oncology.
View the ESMO colloquium details

Learning Objectives

  • Based on case presentations
  • Discuss the best sequence and level of evidence
  • Learn how the use biomarkers in decision making
  • Review the guidelines algorithms and ESMO-MCBS scores as tools for selection

Monday, 30 September 2019

ESMO Colloquium: Pancreatic cancer: Can better understanding of biology improve resectability and survival?

Pancreatic-Cancer-Can-Better-Understanding-of-Biology-Improve-Resectability-and-Survival-CELGENE-Thumb

Alicante Auditorium, 13:00-14:30
This educational activity is provided by ESMO and supported by Celgene.
View the ESMO colloquium details

Learning Objectives

  • Learn on the biological peculiar aspects of pancreatic cancer and treatment resistance
  • Review the present state of art of medical treatment improving resectability and survival
  • Get the point of view of the specialized surgeon on resectabilitiy criteria and issues
  • Review the present development of new drugs including targeted and Immuno-oncology agents

Monday, 30 September 2019

ESMO Colloquium: Recurrent glioblastoma management: Challenges and opportunities

Recurrent-Glioblastoma-Management-Challenges-and-Opportunities-APOGENIX-Thumb

Salamanca Auditorium, 18:30-20:00
This educational activity is provided by ESMO and supported by Apogenix AG.
View the ESMO colloquium details

Learning Objectives

  • Review the present standard of care management of recurrent glioblastoma
  • Access the landscape of present new development for the treatment of recurrent glioblastoma
  • Understand the role and biological mechanisms of CD95/CD95 ligand (Fas/Fas ligand) signaling pathway
  • Deliver an update of the present clinical results of CD95/CD95 ligand (Fas/Fas ligand) blockade